Free Trial

Novozymes A/S (OTCMKTS:NVZMY) Short Interest Down 98.6% in January

Novozymes A/S logo with Basic Materials background

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) saw a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 100 shares, a decline of 98.6% from the January 15th total of 7,300 shares. Based on an average daily volume of 37,700 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Barclays upgraded Novozymes A/S to a "strong-buy" rating in a research report on Monday, November 18th.

View Our Latest Analysis on Novozymes A/S

Novozymes A/S Stock Up 2.8 %

OTCMKTS NVZMY traded up $1.57 during trading hours on Friday, hitting $58.35. 13,577 shares of the company were exchanged, compared to its average volume of 20,193. The company has a 50 day moving average of $56.81 and a two-hundred day moving average of $61.94. Novozymes A/S has a 52-week low of $52.77 and a 52-week high of $72.50. The firm has a market cap of $27.33 billion, a price-to-earnings ratio of 36.93, a PEG ratio of 3.87 and a beta of 0.88.

About Novozymes A/S

(Get Free Report)

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Read More

Should You Invest $1,000 in Novozymes A/S Right Now?

Before you consider Novozymes A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.

While Novozymes A/S currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines